Bosutinib
Top View
- Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
- Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
- Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
- Bosutinib (Bosulif) for Chronic Myeloid Leukemia
- Safety and Efficacy of Second-Line Bosutinib for Chronic Phase Chronic Myeloid Leukemia Over a Five-Year Period: Final Results of a Phase I/II Study
- Tyrosine Kinase Inhibitors and Acute Pancreatitis
- Bladder Cancer
- Clinical Pharmacology of Tyrosine Kinase Inhibitors Becoming Generic
- PF-00299804 Bosutinib Axitinib
- Class Effects of Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
- Pulmonary Arterial Hypertension Associated with Protein Kinase Inhibitors: a Pharmacovigilance- Pharmacodynamic Study
- Pulmonary Arterial Hypertension Associated with Protein Kinase Inhibitors: a Pharmacovigilance–Pharmacodynamic Study
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- Application of Drug–Metal Ion Interaction Principle In
- Global Target Profile of the Kinase Inhibitor Bosutinib in Primary
- Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Adult Antiemetic Management of Chemotherapy-Induced Nausea